Ontology highlight
ABSTRACT:
SUBMITTER: Shen LS
PROVIDER: S-EPMC7213629 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
Chinese medical journal 20200501 9
Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on insights of endocrine resistance mechanisms, a number of targeted therapies have been and continue to be developed. With regard to HR-positive, HER2-negative advanced BC, aromatase inhibitor (AI) is sup ...[more]